



ASX release

22 January 2015

Tax refund

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor® system which noninvasively measures central aortic blood pressures and arterial stiffness, announced today that the company has received a refund from the Australian Tax Office under the R&D tax incentive program of \$461,182.

Half year results will be released later in February, following completion of the audit review.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,600 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 800 peer-reviewed studies published in leading medical journals along with thousands of citations. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

*For further information, please contact
(AtCor):*

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au